SIGN-UP NOW! SIGN-UP NOW! Click to become a VoiceAmerica Member for Free!
Voiceamerica radio logo
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More
top banner

C. diff. Spores and More

Tuesday at 10 AM Pacific

October 31st 2017:Research Update From Summit Therapeutics on Ridinilazole

Join Us With Guest Dr. Richard Vickers, Ph.D., Chief Scientific Officer at Summit Therapeutics joining us to discuss their research on a new antibiotic to treat a C. difficile infection. Learn more about Ridinilazole, clinical trials and the progress being made and moving closer to getting an urgently needed new treatment available for CDI to patients.

Share Email SHARE
Download PDF DOWNLOAD PDF
Get Code GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
LISTEN LIVE
EPISODE ON DEMAND
VIEW HOST PAGE
Questions? Comments?
Call In Live!
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guest

Guest Image

Richard Vickers Ph.D.

Dr. Vickers is Chief Scientific Officer, Antimicrobials and Programme Lead for CDI, Summit Therapeutics. He joined Summit in 2003 and during his time has worked in a variety of roles involved in the development and management of various antibacterial therapeutic programs. This includes leading the discovery and development of ridinilazole, the investigational antibiotic for the treatment of a C. difficile infection. Prior to joining Summit, Dr Vickers undertook postdoctoral research studies with Professor Stephen Davies at the University of Oxford and held a Stipendiary Lectureship in organic chemistry at St. Catherine’s College in Oxford. Dr Vickers received a Ph.D. in organic chemistry f
Read more

Share This Episode

facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn
Share Email Share this E-mail
https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 28/11/2017 10:00 28/11/2017 11:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more Join Us With Guest Dr. Richard Vickers, Ph.D., Chief Scientific Officer at Summit Therapeutics joining us to discuss their research on a new antibiotic to treat a C. difficile infection. Learn more about Ridinilazole, clinical trials and the progress being made and moving closer to getting an urgently needed new treatment available for CDI to patients. VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY Add to Calendar
Email Host Email the Host

Connect with VoiceAmerica

Download our mobile apps
App store Google play Blackberry store
GPlus Facebook Twitter Linkedin Social Media
presspass-banner